Iron in the extracellular body fluids is maintained in solution bound mainly to transferrin (Beam and Parker, 1966) although other forms may exist (Aisen and Leibman, 1968) . Ferrokinetic studies are concerned with the behaviour of transferrin bound iron, and the importance of ensuring that other soluble forms of iron are excluded from a tracer dose has been recognized (Finch, Deubelbeiss, Cook, Eschbach, Harker, Funk, Marsaglia, Hillman, Slichter, Adamson, Ganzoni, and Giblett, 1970) . The two iron-binding sites of transferrin have extremely high affinities for ferric iron (Aasa, Malmstrom, Saltman, and Vanngard, 1963) and it has generally been assumed that iron bound to other ligands, such as citrate, would rapidly and completely bind to any unsaturated transferrin. In preparing ["9Fe ] transferrin a latent iron-binding capacity in serum greater than the amount of added iron should produce complete binding of the tracer to the transferrin. Studies in vivo have thrown doubt on this assumption. When [59Fe] ferric citrate was incubated at 37°C for 30 min with plasma having an excess binding capacity and then injected intradermally up to 40% of the 59Fe was cleared rapidly as unbound ferric citrate (Cavill and Jacobs, 1970 Ferric citrate has an overall charge of -1 (Helbock and Saltman, 1967) and binds strongly to the anion exchange resin IRA 400 in the Clform. The iron-transferrin complex at neutral pH also carries a negative charge but does not exchange readily with the resin. A serum and [59Fe] ferric citrate mixture was passed through an IRA 400
The preparation of 59Fe-labelled transferrin for ferrokinetic studies Elution Volume (ml) Fig. 1 (Amberlite) is prepared in the Cl-form by soaking the resin in 1IN HCI for one hr and is then washed with saline until acid free. The barrel of a 1 ml plastic Mantoux syringe is filled up to the 0-8-1 0 ml mark with moist resin.
Twelve ml venous blood is defibrinated by mixing with depyrogenized glass beads for 15 minutes. Five ml serum is added to not more than 0 5 ml [59Fe] ferric citrate and allowed to stand at room temperature for five minutes. Sufficient "9Fe activity for ferrokinetic studies is usually bound to the transferrin in this time. Of the solution, 0-5 ml is added to the column and the eluate discarded. The remainder is then added and the eluate, containing only transferrin bound 59Fe, is sterilized by passing it through a 0 45 ,um Millipore filter. The percentage 59Fe binding is calculated by counting the activity in an aliquot of solution before and after it has been through the colunmn. The percentage 5Fe binding to the sera of 17 normal subjects, in which the latent iron-binding capacity per 5 ml serum was 2-15 (mean, 3) times greater than the amount of iron added, was between 80 and 100%. The mean value (90%) was significantly less than 100% (t = 5 4913, p < 0 001). Sera from seven iron-deficient patients, in whom the latent iron-binding capacity per 5 ml serum was between 2 and 26 (mean, 8) times the added iron bound between 89 and 1000% of the 59Fe. The mean binding (940%) was significantly less than 1000% (t = 3-6207, p < 0-02) but was not significantly greater than in normal subjects. In five patients with an iron overload, as a result of haemochromatosis or transfusion siderosis, the iron added to their sera was four to 20 times its latent iron-binding capacity per 5 ml serum and 59Fe binding was between 4 and 80%.
Twenty mg purified human transferrin (Behringwerke, A. G. Marburg/Lahn) was dissolved in I. Cavill 0 4 ml [59Fe] ferric citrate, contaiIiing 3-7 ,ug iron. After incubation for one hr at 37°C only 78 % of the 59Fe was transferrin bound. This was considerably less than would be expected and suggests that the iron-binding capacity of the transferrin had been impaired during the purification process.
Although the ratio of the serum latent ironbinding capacity to the iron added is an important factor governing the percentage 59Fe binding it seems likely that a high citrate:iron ratio may also have an effect (Bates, Billups, and Saltman, 1967) . These results show that an excess latent iron-binding capacity, which may occur in both normal and irondeficient patients, does not ensure complete 59Fe binding in the presence of a high citrate concentration. In order to ensure that only 59Fe bound to transferrin is used as a tracer in ferrokinetic studies all preparations should be passed through an anion exchange column before use to remove any unbound ferric citrate. This is especially important in patients with a reduced latent iron-binding capacity. 
